nach oben

Erschienen in:

01.09.2016 | original article

Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities

verfasst von: Jana Figurová, MD, Ingrid Dravecká, MD, PhD, Martin Javorský, MD, PhD, Jana Petríková, MD, PhD, Prof. Ivica Lazúrová, MD, FRCP, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2016

Einloggen, um Zugang zu erhalten

Summary

Objective

To investigate prevalence of vitamin D deficiency and its relation to clinical, anthropometrical, and biochemical findings in polycystic ovary syndrome (PCOS) and controls.

Design

Case-control prospective observational study.

Settings

Department of Internal medicine, L.P. University hospital.

Patient(s)

99 PCOS women and 66 controls.

Main outcome measure(s)

25-hydroxyvitamin D level (25(OH)D), anthropometric, endocrine, and metabolic parameters in both groups.

Results

There was no significant difference in 25(OH)D levels between PCOS women and controls (24.79 ± 10.77 vs 25.07 ± 10.14 ng/ml, p = 0.868) and also in the prevalence of 25(OH)D deficiency in both groups (80 vs 70 %; p = 0.138). Vitamin D-deficient PCOS patients had significantly higher body mass index (BMI), fasting insulin, and homeostasis model assessment-insulin resistance (median [quartiles]: 2.24 [1.38; 3.51] vs 1.23 [0.79; 1.66]; p< 0.05, age-and BMI-adjusted p = 0.036) and borderline higher glycemia (4.7 ± 0.5 vs 4.5 ± 0.4 mmol/l; p = 0.05; p_adj = 0.95) compared with vitamin D-deficient controls. PCOS women with metabolic syndrome (MS) had lower serum 25(OH)D compared with those without MS (20.6 ± 8.3 vs 25.9 ± 11.3 ng/ml, p = 0.049). 25(OH)D correlated positively with high-density lipoprotein cholesterol in all subjects (r = 0.159, p = 0.043) and negatively with luteinizing hormone/follicle-stimulating hormone ratio (r = − 0.211, p = 0.037).

Conclusion

Insulin resistance and other metabolic abnormalities in PCOS women seem to be related to PCOS rather than to vitamin D deficiency.

Vorheriger Artikel Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

Nächster Artikel Current practice in neurocritical care of patients with subarachnoid haemorrhage and severe traumatic brain injury

March WA, Moore VM, Willsen KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51.CrossRefPubMed

Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med. 2006;166(19):2081–6.CrossRefPubMed

Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24(3):302–12.CrossRefPubMed

Ortlepp JR, Metrikat J, Albrecht M, von Korff A, Hanrath P, Hoffmann R. The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med. 2003;20(6):451–4.CrossRefPubMed

Hahn S, Haselhorst U, Tan S, Quadbeck B, Schmidt M, Roesler S. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2006;114(10):577–83.CrossRefPubMed

Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161(4):575–82.CrossRefPubMed

Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin HG, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(4):559–63.CrossRefPubMed

Mahmoudi T. Genetic variation in the vitamin D receptor and polycystic ovary syndrome risk. Fertil Steril. 2009;92(4):1381–3.CrossRefPubMed

Thomson RL, Spedding S, Buckley JD. Vitamin D in aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77(3):343–50.CrossRef

10.

Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.CrossRefPubMed

11.

National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel III). Circulation. 2002;106:3143–421.

12.

Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. Clin Endocrinol Metab. 2013;98(8):1283–304.CrossRef

13.

Weinstock-Guttman B, Zivadinov R, Ramanathan M. Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci. 2011;311(1–2):86–91.CrossRefPubMed

14.

Li HWR, Brereton RE, Anderson RA, Wallace AM, Co HK. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60(10):1475–81.CrossRefPubMed

15.

Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, et al. Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem. 2005;51(9):1691–7.CrossRefPubMed

16.

Kim JJ, Choi YM, Chae SJ, et al. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med. 2014;41(2):80–5.CrossRefPubMedPubMedCentral

17.

Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011;164(5):741–9.CrossRefPubMed

18.

Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril. 2010;93(4):1208–14.CrossRefPubMed

19.

Lips P. Worldwide status of vitamin D nutrition. J Steroid Bioch Mol Biol. 2010;121(1–2):297–300.CrossRef

20.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–81.CrossRefPubMed

21.

Patra SK, Nasrat H, Goswami B, Jain A. Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome. Diabetes Metab Syndr. 2012;6(3):146–9.CrossRefPubMed

22.

Ngo DT, Chan WP, Rajendran S, et al. Determinants of insulin responsiveness in young women: impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide. 2011;25(3):326–30.CrossRefPubMed

23.

Krul-Poel YH, Snackey C, Louwers Y, et al. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review. Eur J Endocrinol. 2013;169(6):853–65.CrossRefPubMed

24.

Tsakova AD, Gateva AT, Kamenov ZA. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res. 2012;82(6):399–404.CrossRefPubMed

25.

Sahin S, Eroglu M, Selcuk S, et al. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2014;18(19):2851–6.PubMed

26.

Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, et al. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin Nutr. 2012;31(4):476–80.CrossRefPubMed

27.

Teegarden D, Donkin SS. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev. 2005;22(1):85–92.

28.

Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2813–8.CrossRefPubMed

29.

Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol. 2011;164(5):741–9.CrossRefPubMed

30.

Ardabili HR, Gargari BP, Farzadi L. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res. 2012;32(3):195–201.CrossRefPubMed

31.

Bonakdaran S, Mazloom Khorasani Z, Davachi B, Mazloom Khorasani J. The effects of calcitriol on improvement of insulin resistance, ovulation and comparison with metformin therapy in PCOS patients: a randomized placebo-controlled clinical trial. Iran J Reprod Med. 2012;10(5):465–72.PubMedPubMedCentral

32.

Raja-Khan N, Shah J, Stetter CM, et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: a randomized, controlled pilot trial. Fertil Steril. 2014;101(6):1740–6.CrossRefPubMedPubMedCentral

33.

Selimoglu H, Duran C, Kiyici S, et al. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest. 2010;33(4):234–8.CrossRefPubMed

34.

Killkinen A, Knekt P, Aro A, Rissanen H, Marniemi J, Heliövaara M, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidem. 2009;170(8):1032–9.CrossRef

35.

Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011;50(4):303–12.CrossRefPubMed

36.

Glintborg D, Andersen M, Hagen C, Hermann AP. Higher bone mineral density in Caucasian, hirsute patients of reproductive age. Positive correlation of testosterone levels with bone mineral density in hirsutism. Clin Endocrinol. 2005;62(6):683–91.CrossRef

37.

Pal L, Shu J, Zeitlian G. Vitamin D insufficiency in reproductive years may be contributory to ovulatory infertility and PCOS. Fertil Steril. 2008;90:14.CrossRef

Titel: Prevalence of vitamin D deficiency in Slovak women with polycystic ovary syndrome and its relation to metabolic and reproductive abnormalities
verfasst von: Jana Figurová, MD
Ingrid Dravecká, MD, PhD
Martin Javorský, MD, PhD
Jana Petríková, MD, PhD
Prof. Ivica Lazúrová, MD, FRCP, PhD
Publikationsdatum: 01.09.2016
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 17-18/2016
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-015-0768-9

Springer Medizin Österreich

Summary

Objective

Design

Settings

Patient(s)

Main outcome measure(s)

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2016

The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging

The neutrophil–lymphocyte ratio as an inflammatory marker in acute exacerbation of COPD

Current practice in neurocritical care of patients with subarachnoid haemorrhage and severe traumatic brain injury

Metachronous gallbladder metastasis from renal cell carcinoma—a rare clinical manifestation

Malignant pleural mesothelioma